Concordance of HER-2/Neu over Expression with Steroid Receptor Status in Female Breast Cancers


HER-2/neu over expression is associated with increased tumor aggressiveness, increased rates of recurrence, and increased mortality in node positive patients. It is amplified and/or over expressed in approximately 30% of female breast cancers. This study was to detect the relation between HER-2/neu over expression and steroid hormone receptor status. It was conducted at Cairo and Bani Suif university hospitals between February 2012 to February 2014. HER-2/neu over expression was found to be positive in thirteen patients (41%) out of the thirty two patients included in the study, more positive (52%) HER-2/neu was found among estrogen receptor (ER) positive patients, on the other hand, only 18% positive HER-2/neu was detected among ER negative patients. This difference was statistically significant (P < 0.03). The same outcome was with progesterone receptors (PR) and HER-2/neu with statistically significant difference also (P = 0.02). Conclusion: HER-2/neu over expression is strongly related to ER and PR, this was more evident in negative steroid receptors status. The failure of treatment in positive steroid receptors could be explained by HER-2/neu positivity.


HER-2/Neu, ER, PR

Share and Cite:

Abdelhamid, M. , Abdelaziz, S. , Daoud, S. , Sadat, A. , Abdelhaseeb, A. , Nabil, T. , Abdelbasset, M. , Nafady, H. , Shawky, K. and Abdelmoola, M. (2014) Concordance of HER-2/Neu over Expression with Steroid Receptor Status in Female Breast Cancers. Surgical Science, 5, 354-362. doi: 10.4236/ss.2014.58058.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Grosvor, C.E. and Picciano, F.C. (2005) Hormones and Growth Factors Milk. Endocrine Reviews, 61, 413-417.
[2] Vonderhaar, B.K. (2003) Regulation of Development of Mammary Gland. Cancer Treatment and Research, 40, 551-559.
[3] Daly, J.M., Bertagnolli, M., Decosse, J.J., et al. (1999) Oncology. In: Schwartz, S.I., Ed., Principles of Surgery, 7th Edition, Mc Grow-Hill, New York, 297-360.
[4] Weiss, L.M. (2003) Breast. In: Weidner, N., Cote, R.J., and Weiss, L.M., Eds., Modern Surgical Pathology, 1st Edition, Saunders, Philadelphia, 599-672.
[5] Rosai, J. (2004) Breast. In: Rosai, J., Ed., Rosai and Acker Man’s Surgical Pathology, 9th Edition, Mosby, Edinburgh, 1763-1876.
[6] Licznar, A., Caporali, S., Lucas, A., et al. (2003) Identification of Genes Involved in Growth Inhibition of Breast Cancer. FEBS Letters, 23, 445-450.
[7] Dickson, R.B. and Lippman, M.E. (1997) Cancer of the Breast. In: Devita, V.T., Hellman, S. and Rosenberg, S.A., Eds., Cancer, 5th Edition, Lippincott, Philadelphia, 1541-1553.
[8] Cianfrocca, M. and Goldstein, L.J. (2004) Prognostic and Predictive Factors in Early Stage Breast Cancer. The Oncologist, 9, 606-616.
[9] Al Saati, T. (1993) Production of Monoclonal Antibodies in Human Oestrogen Protein Recptor. International Journal of Cancer, 55, 651.
[10] Kell, D.L. (2003) Immunohistochemical Analysis of Breast Carcinoma Estrogen and Progesterone Receptor. Applimmunohisch, 1, 275.
[11] Koeppen, H.K.W., Wright, B.D., Burt, A.D., et al. (2001) Over Expression of HER-2-Neu an Immunohistochemical Survey. Histopathology, 38, 96-104.
[12] Swinscow, T.D.V. and Campell, M.J. (1996) Statistics at Square One. In: Swinscow, T.D.V., Ed., 9th Edition, Plymouth Latimer Trend Company Ltd., 1-139.
[13] Mitri, Z., Constantine, T. and O’Regan, R. (2012) The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. Chemotherapy Research and Practice, 2012, Article ID: 743193.
[14] Kaufmann, R., Müller, P., Hildenbrand, G., Hausmann, M. and Cremer, C. (2011) Analysis of Her2/Neu Membrane Protein Clusters in Different Types of Breast Cancer Cells Using Localization Microscopy. Journal of Microscopy, 242, 46-54.
[15] Nyagol, J., Nyong’o, A., Byakika, B., Muchiri, L., Cocco, M., de Santi, M.M., Spina, D., Bellan, C., Lazzi, S., Kostopoulos, I., Luzi, P. and Leoncini, L. (2006) Routine Assessment of Hormonal Receptor and Her-2/Neu Status Underscores the Need for More Therapeutic Targets in Kenyan Women with Breast cancer. Analytical and Quantitative Cytology and Histology, 28, 97-103.
[16] Schmitt, F.C., Figueiredo, P. and Lacarda, M. (1995) Exxpression of C-erb B-2 Protein and DNA Ploidy in Breast Carcinogenesis. Archives of Pathology Laboratory Medicine, 119, 815-820.
[17] Pierce, L.J., Merino, M.J., D’angelo, et al. (1994) Is C-erb B-2 a Predictor for Recurrent Disease in Early Stage Breast Cancer. International Journal of Radiation Oncology * Biology * Physics, 28, 395-403.
[18] Wang, W., Saluaga, R., et al. (2003) Gene Expression Signature Associated with Clinical Outcome in Breast Cancer. British Cancer Research, 82, 29-34.
[19] Huang, H.J., Neven, P., Drij Koningen, M., et al. (2005) Association between HER-2-Neu and Progesterone Receptor in Oestrogen Dependent Breast Cancer Is Age Related. Breast Cancer Research and Treatment, 91, 81-87.
[20] O’ Malley, F.P., Saad, Z., Kerkuliet, N., et al. (1996) The Predictive Power of Semi Quantitative Immunohistochemial Assessment of p53 and c-erb B-2 in Lymph Node Negative Breast Cancer. Human Pathology, 27, 955-963.
[21] Jing, X., Kakudo, K., Murakami, M., et al. (1999) Intraductal Spread of Breast Carcinoma Has a Positive Correlation with C-erb B-2 over Expression. Cancer, 86,439-448.<439::AID-CNCR12>3.0.CO;2-U

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.